RIVAROXABAN: AN ORAL DIRECT INHIBITOR OF FACTOR X-A
Journal Title: International Research Journal of Pharmacy (IRJP) - Year 2011, Vol 2, Issue 8
Abstract
Venous thrombo embolism (VTE), which includes deep vein thrombosis and pulmonary embolism, is a major cause of morbidity and mortality in patients undergoing major orthopaedic surgery, and routine thrombo prophylaxis has been the standard of care over the last 20 years. Currently available options for the prevention of venous thrombo embolism in major orthopedic surgery include low-molecular-weight heparins, vitamin K antagonists and, more recently, the synthetic pentasaccharide fondaparinux. Although effective, these drugs have several limitations, and new oral antithrombotics offering predictable, effective and safe anticoagulation are strongly needed. This overview focuses on the most advanced oral direct inhibitors of factor Xa, rivaroxaban. Rivaroxaban, an oral oxazolidinone-based anticoagulant, is a potent, selective direct inhibitor of factor Xa that is used in the prevention of venous thrombo embolism in adult patients after total hip replacement (THR) or total knee replacement (TKR) surgery. In four large, clinical trials, oral rivaroxaban was more effective than subcutaneous enoxaparin in preventing postoperative VTE in patients undergoing total hip replacement or total knee replacement surgery. Notably, the superior efficacy of rivaroxaban was achieved with a low but not significant increase in the incidence of major bleeding episodes. In addition, preliminary pharma co-economic analyses in several countries indicate that rivaroxaban is a cost-effective treatment strategy versus enoxaparin. Although the position of rivaroxaban relative to other therapies remains to be fully determined, it is an effective emerging option for the prevention of venous thrombo embolism following total hip replacement and total knee replacement.
Authors and Affiliations
Hiren Mehta , Paresh Patel , Varsha Galani
Keywords
Related Articles
- EP ID EP103283
- DOI -
- Views 82
- Downloads 0
EVALUATION OF PATIENT’S ANTIDIABETIC MEDICATION COUNSELLING PROVIDED BY PHARMACISTS IN A TERTIARY HEALTH CARE SETTING IN NIGERIA
The objective of the present study was to ascertain the level of patient’s anti-diabetic medication counselling provided by Pharmacists. Seventy two (72) outpatients that visited the consultant outpatient clinic of the e...
ANTIOXIDANT ACTIVITY OF MAJORANA HORTENSIS LEAVES SUBJECTED TO OXIDATIVE STRESS IN AN IN VITRO SYSTEM
Oxidative stress can arise from an imbalance between the generation and elimination of reactive oxygen species leading to the excess levels, which in turn cause various diseases and cell death. Reactive oxygen species c...
HIGH PERFORMANCE THIN LAYER CHROMATOGRAPHIC DETERMINATION OF CILNIDIPINE AND TELMISARTAN IN COMBINED TABLET DOSAGE FORM
A new simple high performance thin layer chromatography (HPTLC) method for determination of Cilnidipine and Telmisartan in combined dosage form has been developed and validated. The separation was carried out on Merck al...
POLYMER: A BOON TO CONTROLLED DRUG DELIVERY SYSTEM
Polymer plays a vital role in novel drug delivery systems with its longevity and self-transforming quality as excipient in tablet and capsule formulations. Use of polymer is now extended to controlled-release and drug-ta...
FINDING NEW INHIBITORS FOR EML4-ALK FUSION PROTEIN: A COMPUTATIONAL APPROACH
The fusion between echinoderm microtubule-associated protein-like 4 (EML4) and anaplastic lymphoma kinase (ALK) has recently been identified in a subset of non-small cell lung cancers (NSCLC). PF-02341066 (crizotinib) is...